Following a story · 3 updates
PROGRESS trial favors valve replacement in moderate aortic stenosis
Oct 27, 2026 – Nov 8, 2026
-
TCT 2026 trials that bear on coverage
The Transcatheter Cardiovascular Therapeutics meeting runs October 31 to November 3 in San Diego with 28 late-breaking studies, including PROGRESS on TAVR in moderate aortic stenosis, and no results are public yet.
Read this issue → -
PROGRESS TAVR trial scheduled Monday
The PROGRESS randomized trial of valve replacement versus clinical surveillance in moderate aortic stenosis is scheduled for primary results on Monday, November 2, with no results found yet.
Read this issue → -
PROGRESS trial favors valve replacement in moderate aortic stenosis
In 744 patients with moderate aortic stenosis and at-risk features, Edwards' Sapien 3 produced death or heart-failure events in 16.7 percent versus 23.9 percent with surveillance at two years, with similar all-cause mortality.
Read this issue →